Abstract
The bone microenvironment plays a critical role in tumor-induced osteolysis and osteolytic metastasis through tumor-bone (TB)-interaction. Receptor activator of nuclear factor-κB (RANK) ligand (RANKL) is one of the critical signaling molecules involved in osteolysis and bone metastasis. However, the regulation and functional significance of RANKL at the TB-interface in tumor-induced osteolysis remains unclear. In this report, we examined the role of tumor-stromal interaction in the regulation of RANKL expression and its functional significance in tumor-induced osteolysis. Using a novel mammary tumor model, we identified that RANKL expression was upregulated at the TB-interface as compared to the tumor alone area. We demonstrate increased generation of sRANKL at the TB-interface, which is associated with tumor-induced osteolysis. The ratio of RANKL to osteoprotegrin (OPG), a decoy receptor for RANKL, at the TB-interface was also increased. Targeting RANKL expression with antisense oligonucleotides (RANKL-ASO), significantly abrogated tumor-induced osteolysis, decreased RANKL expression and the RANKL:OPG ratio at the TB-interface. Together, these results demonstrate that upregulation of RANKL expression and sRANKL generation at the TB-interface potentiates tumor-induced osteolysis.
Original language | English (US) |
---|---|
Pages (from-to) | 797-808 |
Number of pages | 12 |
Journal | Clinical and Experimental Metastasis |
Volume | 26 |
Issue number | 7 |
DOIs | |
State | Published - Oct 2009 |
Keywords
- Anti-sense therapeutics
- Bone metastasis
- RANKL
- Soluble RANKL
- Tumor-bone interaction
- Tumor-induced osteolysis
ASJC Scopus subject areas
- Oncology
- Cancer Research